191 related articles for article (PubMed ID: 19690146)
41. [Effects of 17-DMAG on non-small cell lung cancer cell lines A549 and H1975
being resistant to EGFR-TKI].
Zhao L; Cao F
Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):778-82. PubMed ID: 25404267
[TBL] [Abstract][Full Text] [Related]
42. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Sobue G
Ann N Y Acad Sci; 2006 Nov; 1086():21-34. PubMed ID: 17185503
[TBL] [Abstract][Full Text] [Related]
43. 17-DMAG, an Hsp90 inhibitor, ameliorates ovariectomy-induced obesity in rats.
Tsai YC; Leu SY; Chen SY; Kung CW; Lee YM; Liu YP; Yen MH; Cheng PY
Life Sci; 2019 Sep; 232():116672. PubMed ID: 31336120
[TBL] [Abstract][Full Text] [Related]
44. Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis.
Palacios C; Martín-Pérez R; López-Pérez AI; Pandiella A; López-Rivas A
Leuk Res; 2010 Nov; 34(11):1533-8. PubMed ID: 20667592
[TBL] [Abstract][Full Text] [Related]
45. 17-DMAG, an HSP90 Inhibitor, Ameliorates Multiple Organ Dysfunction Syndrome via Induction of HSP70 in Endotoxemic Rats.
Wang YL; Shen HH; Cheng PY; Chu YJ; Hwang HR; Lam KK; Lee YM
PLoS One; 2016; 11(5):e0155583. PubMed ID: 27224288
[TBL] [Abstract][Full Text] [Related]
46. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
[TBL] [Abstract][Full Text] [Related]
47. Co-inhibition of HSP70/HSP90 synergistically sensitizes nasopharyngeal carcinoma cells to thermotherapy.
Cui XB; Yu ZY; Wang W; Zheng YQ; Liu W; Li LX
Integr Cancer Ther; 2012 Mar; 11(1):61-7. PubMed ID: 21498475
[TBL] [Abstract][Full Text] [Related]
48. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Holmes JL; Sharp SY; Hobbs S; Workman P
Cancer Res; 2008 Feb; 68(4):1188-97. PubMed ID: 18281495
[TBL] [Abstract][Full Text] [Related]
49. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
Pacey S; Wilson RH; Walton M; Eatock MM; Hardcastle A; Zetterlund A; Arkenau HT; Moreno-Farre J; Banerji U; Roels B; Peachey H; Aherne W; de Bono JS; Raynaud F; Workman P; Judson I
Clin Cancer Res; 2011 Mar; 17(6):1561-70. PubMed ID: 21278242
[TBL] [Abstract][Full Text] [Related]
50. 17 AAG for HSP90 inhibition in cancer--from bench to bedside.
Usmani SZ; Bona R; Li Z
Curr Mol Med; 2009 Jun; 9(5):654-64. PubMed ID: 19601813
[TBL] [Abstract][Full Text] [Related]
51. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
[TBL] [Abstract][Full Text] [Related]
52. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.
Powers MV; Clarke PA; Workman P
Cancer Cell; 2008 Sep; 14(3):250-62. PubMed ID: 18772114
[TBL] [Abstract][Full Text] [Related]
53. Drug-Induced HSP90 Inhibition Alleviates Pain in Monoarthritic Rats and Alters the Expression of New Putative Pain Players at the DRG.
Nascimento DSM; Potes CS; Soares ML; Ferreira AC; Malcangio M; Castro-Lopes JM; Neto FLM
Mol Neurobiol; 2018 May; 55(5):3959-3975. PubMed ID: 28550532
[TBL] [Abstract][Full Text] [Related]
54. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.
Castro JE; Prada CE; Loria O; Kamal A; Chen L; Burrows FJ; Kipps TJ
Blood; 2005 Oct; 106(7):2506-12. PubMed ID: 15972449
[TBL] [Abstract][Full Text] [Related]
55. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
56. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
57. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
Smith MA; Morton CL; Phelps DA; Kolb EA; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Wu J; Houghton PJ
Pediatr Blood Cancer; 2008 Jul; 51(1):34-41. PubMed ID: 18260120
[TBL] [Abstract][Full Text] [Related]
58. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.
Lang SA; Moser C; Gaumann A; Klein D; Glockzin G; Popp FC; Dahlke MH; Piso P; Schlitt HJ; Geissler EK; Stoeltzing O
Clin Cancer Res; 2007 Nov; 13(21):6459-68. PubMed ID: 17975158
[TBL] [Abstract][Full Text] [Related]
59. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.
Abramson JS; Chen W; Juszczynski P; Takahashi H; Neuberg D; Kutok JL; Takeyama K; Shipp MA
Br J Haematol; 2009 Feb; 144(3):358-66. PubMed ID: 19036086
[TBL] [Abstract][Full Text] [Related]
60. Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
Chen JC; Ko JC; Taso YC; Cheng HH; Chen TY; Yen TC; Lin YW
Pharmacology; 2021; 106(3-4):154-168. PubMed ID: 33202406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
